LYON, France--(BUSINESS WIRE)--Regulatory News: These encouraging findings from the IASO Phase 1b trial confirm the favorable safety and tolerability profile of MaaT033 in ALS patients. They also ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback